Efficacy and Safety of Ramucirumab Plus Carboplatin and Paclitaxel for Untreated Metastatic Thymic Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)
Ann. Oncol 2024 Jun 08;[EPub Ahead of Print], C Proto, M Ganzinelli, S Manglaviti, M Imbimbo, G Galli, M Marabese, F Zollo, MF Alvisi, M Perrino, N Cordua, F Borea, F de Vincenzo, A Chella, S Cappelli, E Pardini, Z Ballatore, A Lucarelli, E Ambrosini, M Giuliano, E Pietroluongo, C Mulargiu, A Fabbri, A Prelaj, M Occhipinti, M Brambilla, L Mazzeo, T Beninato, R Vigorito, M Ruggirello, FG Greco, G Calareso, D Miliziano, E Rulli, I De Simone, V Torri, FGM de Braud, G Pasello, P De Placido, R Berardi, I Petrini, P Zucali, MC Garassino, G Lo RussoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.